During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lymphocytic leukemia (CLL) from the meeting.

Brody highlights several presentations on approved and novel immunotherapies for patients with lymphoma and CLL. He discusses the significant progress made in the treatment of B-cell non-Hodgkin lymphoma (NHL). He also discusses the historically poor outcomes in patients with T-cell lymphoma and highlights some of the novel therapies presented at ASH for this patient population.

Hosted on Acast. See acast.com/privacy for more information.